Head-to-head evidence
pemvidutide vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
pemvidutide
Developed by Altimmune
NCT05989711 · Phase 2 · completed
This randomised, quadruple-blind, placebo-controlled trial in 212 patients with MASH used resolution of steatohepatitis without worsening fibrosis as its primary endpoint, a biopsy-based clinical measure.
Next expected readout: December 2028 · NCT07795164 (registry estimate)
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06309992 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial in 218 participants met both of its co-primary endpoints: a much larger share of survodutide-treated participants achieved at least 30% liver fat reduction (84.2% vs 24.3% on placebo) and lost significantly more body weight (-12.2% vs -1.0%), both highly statistically significant.
Next expected readout: April 2029 · NCT07850063 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pemvidutide's landscape · survodutide's landscape